Cytori Reports 3rd Quarter 2009 Financial Results

  Consolidated Condensed Statements of Operations (Unaudited)     For the Three Months Ended September 30, For the Nine Months Ended September 30, 2009   2008 2009   2008   Product revenues: Related party $ 9,000 $ — ...
Click here to read the whole Article (external link)

CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers (e) Compensatory Arrangements of Certain Officers On October 29, 2009, the Board of Directors of the Company directed the Company to enter into individual change of control agreements (in form approved by the Board of Directors as filed with the Company's 2007 Form 10K on March 14, 2008) (the "Agreements") with Mr. Seijiro Shirahama, President Asia-Pacific, and Mr. Bruce Reuter, Senior Vice President of U.S. Sales, each a "named executive officer". The Agreements will provide for certain severance benefits to be paid to each of these executives in the event of his involuntary termination without cause, or due to the executive's resignation for good reason (including the Company's material breach of its obligations, material reduction in duties, responsibilities, compensation or benefits, or relocation by more than 30 miles without prior consent), provided such termination or resignation occurs in connection with an acquisition of the Company. Upon such termination or resignation, Mr. Shirahama would receive a lump sum payment of 12 times his monthly base salary, and 12 times his monthly COBRA payments and Mr. Reuter will receive a lump sum payment of 6 times his monthly base salary and 6 times his monthly COBRA payments. Notwithstanding the foregoing, these executives' employment may be terminated for cause (including extended disability, repudiation of the Agreement, conviction of a plea of no contest to certain crimes or misdemeanors, negligence that materially harms the company, failure to perform material duties without cure, drug or alcohol use that materially interferes with performance, and chronic unpermitted absence) without triggering an obligation for the Company to pay severance benefits under the Agreements. In addition, under the Agreements, any unvested stock options granted to each of ...
Click here to read the whole Article (external link)

Cytori Therapeutics to Webcast Third Quarter Financial Results on November 9, 2009

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

Q3 2009 Cytori Therapeutics Earnings Release - 07:00 am ET

Earnings Announcements for Monday, November 9CompanySymbolTimeConferenceCall4Kids EntertainmentKDEBefore Market OpenAbatixABIX.PKAfter Market CloseAbraxas PetroleumAXASAfter Market CloseListenACADIA PHARMACEUTICALS INCACADAfter Market CloseADVANCED BATTERY TECHNOLOG INCABATAfter Market CloseAdvanced PhotonixAPIAfter Market CloseListenAdvanta CorporationADVNATime Not SuppliedAdvocatAVCAAfter Market CloseListenAlbany Molecular ResearchAMRIBefore Market OpenAlesco Financial Inc.AFNAfter Market CloseAlexza Pharmaceuticals Inc.ALXAAfter Market CloseListenAlliance One International, Inc.AOIAfter Market CloseAllianz SEAZSEY.PK01:30 am ETListenALLION HEALTHCARE INCALLITime Not SuppliedALPHATEC HOLDINGS INCATECTime Not SuppliedAmerican CareSource Holdings, Inc.ANCIAfter Market CloseA...
Click here to read the whole Article (external link)

Cytori Therapeutics 3rd Qtr Results Call scheduled for 10:30 am ET today

Call DetailsCytori Therapeutics 3rd Qtr Results CallMon, Nov 9, 2009, 10:30 am EasternAbout Cytori Therapeutics (NasdaqGM:CYTX)Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution System family of products, which processes patients' cells at the bedside in real time. Each member of the Celution System family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. The company also offers Celution 800/CRS System for the European cosmetic and reconstructive surgery market through a network of medical distributors; and the Celution 900/MB in Japan through its commercialization partner as part of the StemSource Cell Bank, which prepares cells for cryopreservation. Cytori Therapeutics is conducting two clinical trials on adipose-derived stem and regenerative cells processed with the Celution 600 System in patients suffering from chronic myocardial ischemia and in heart attack patients. In addition, it develops and sells thin film bioresorbable implants in Japan. Further, the company operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Additionally, it has a joint venture with Olympus Corporation to develop and manufacture second generation devices based on its Celution system. The company was founded in 1996 and is headquartered in San Diego, California.More Info:Quote |...
Click here to read the whole Article (external link)

CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition

Show all filings for CYTORI THERAPEUTICS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for CYTORI THERAPEUTICS, INC. 9-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informatio...
Click here to read the whole Article (external link)

Cytori Therapeutics Q3 2009 Earnings Call Transcript

Cytori Therapeutics Inc. (CYTX) Q3 2009 Earnings Call November 9, 2009 10:30 am ET Executives Christopher J. Calhoun - Chief Executive Officer, Director Marc H. Hedrick M.D. - President, Director Mark E. Saad - Chief Financial Officer Analysts Brian Gagnon - Gagnon Securities Joe Feshbach - Joe Feshbach Partners Ren Benjamin - Rodman & Renshaw Erica Layon (ph) - Noble Financial Jason Napodano – Zacks Investment Research Stephen Brozak - Westfield, Bakerink, Brozak Stephen Dunn - Jesup Lamont Neil Gagnon - Gagnon Securities Bart Blout - Sawtooth Capital Presentation Operator Good day ladies and gentlemen. Thank you for standing by. Welcome to the third quarter financial result conference call. During today’s presentation all parties will be in a listen only mode. Following the presentation the conference will be open for questions. (Operator’s instructions) This conference is being recorded today, Monday, November 9, 2009. I would now like to turn the conference over to our host and CEO, Mr. Chris Calhoun. Please go ahead, sir. Christopher J. Calhoun Thanks Jeremy. Good morning. And welcome to Cytori Therapeutics third quarter 2009 conference call. Before we begin, we want to advise that over the course of our call and question and answer session, forward-looking statements will be made regarding events, trends and business prospects which may affect our future operating results and financial position. Some of these risks and uncertainties are described under the risk factor section in Cytori Security a...
Click here to read the whole Article (external link)

Cytori Completes Enrollment in International Breast Cancer Reconstruction Study; Interim Data to Be Presented Dec. 12 at San Antonio Breast Cancer Symposium

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX - News) completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer. Interim data on the first 32 patients who have reached the six-month follow-up will be presented as a poster at the San Antonio Breast Cancer Symposium December 12, 2009 at 7 a.m. U.S. Central Time by Mrs. Eva Weiler-Mithoff, MD, lead investigator at the Glasgow Royal Infirmary. The Cell-Enriched Breast Reconstruction procedure combines a patient’s own naturally occurring adipose-derived regenerative cells (ADRCs) with their fat tissue. This cell-enriched fat graft is then injected into and around the defect area. In the RESTORE 2 study, the ADRCs were extracted from adipose tissue using Cytori’s Celution®800 System. Currently, there is no generally accepted reconstructive method for partial mastectomy patients as the majority of these women are not implant candidates, leaving patients with limited options.The RESTORE 2 study is a prospective, multi-center, post-marketing study in which all patients were treated with their own ADRCs and fat tissue. The study is designed to assess patient and physician satisfaction, improvement in overall breas...
Click here to read the whole Article (external link)

CYTORI THERAPEUTICS, INC. Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)